← Back to Search
A Systematic Review And Meta-analysis Of Second-line Therapies For Treatment Of Mesothelioma.
F. Petrelli, R. Ardito, B. Conti, A. Coinu, M. Cabiddu, M. Ghilardi, K. Borgonovo, S. Barni, A. Ghidini
Published 2018 · Medicine
Download PDFAnalyze on Scholarcy
INTRODUCTION Advanced malignant pleural mesothelioma (MPM) is generally treated with platinum/pemetrexed-based first-line therapy. Once the disease progresses, evidence for the efﬁcacy of palliative treatments is lacking, and platinum re-challenge or single-agent chemotherapy are commonly used. To assess the effects of cytostatic or targeted therapy for treating MPM, we performed a systematic review and meta-analysis. MATERIAL AND METHODS PubMed, the Cochrane Library, and Embase databases were searched to identify published articles on second-line treatments for recurrent or advanced mesothelioma. Inclusion criteria were publication in the English language, describing clinical trials with 20 or more patients, and evaluability for efficacy and for receiving second-line systemic therapies. Data were pooled using number of events/number of evaluable patients, median overall survival (OS) and progression-free survival (PFS), according to a fixed or random effect model. Pooled median OS was the primary endpoint. RESULTS A total of 49 eligible studies (n = 3938 patients; range, 12-400) were identified. Median progression-free survival (PFS) was 3.4 months (95%CI 2.87-3.93). Median pooled OS was 7.86 (95%CI 7.01-8.72). The pooled overall response rate (ORR) was 8.63% (95%CI 6-11.26), and the pooled disease control rate (DCR) was 54.8% (95%CI 48.9-60.6). Median pooled OS with platinum- and pemetrexed-based chemotherapy were 7.93 and 7.78 months, respectively. CONCLUSIONS There remains uncertainty about the ideal second-line agent for MPM. Based on this meta-analysis, palliative chemotherapy or other experimental agents can be considered for patients with MPM who desire further treatment after their disease has progressed, during or after first-line therapy.
This paper references
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
A. Xanthopoulos (2008)
Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study
Ioannis S Tourkantonis (2011)
Introduction, comparison, and validation of Meta‐Essentials: A free and simple tool for meta‐analysis
R. Suurmond (2017)
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
Christine Raynaud (2015)
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
A. Nowak (2013)
Operating characteristics of a rank correlation test for publication bias.
C. Begg (1994)
Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study
Hasan Hüseyin Mutlu (2014)
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
S. Ramalingam (2009)
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
V. Gregorc (2010)
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
Bias in meta-analysis detected by a simple, graphical test
M. Egger (1997)
Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
J. Steer (2010)
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment
J. Sørensen (2007)
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma
D. Fennell (2007)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
M. Reck (2010)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy
Gouji Toyokawa (2013)
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival
J. Beebe-Dimmer (2016)
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
Malignant pleural mesothelioma: A single-center experience in Turkey
A. Sezer (2014)
Measuring inconsistency in meta-analyses
J. Higgins (2003)
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
G. Pasello (2011)
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma.
Arthur Kostron (2016)
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
A Phase II Study of PF‐03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207
P. Wheatley-Price (2016)
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
N. Campbell (2012)
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report
A. Dudek (2012)
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
Seyda Gunduz (2014)
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz (2011)
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
C. Porta (2005)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
Phase II trial of ZD0473 as second-line therapy in mesothelioma.
G. Giaccone (2002)
The clinicopathological characteristics with long-term outcomes in malignant mesothelioma
Mutlu Dogan (2014)
Chemotherapy in malignant pleural mesothelioma. A review.
S. T. Ong (1996)
Bias in meta-analysis detected by a simple, graphical test
J. Vandenbroucke (1998)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
N. S. Patil (2018)
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
S. Laurie (2017)
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
D. Fennell (2012)
This paper is referenced by
Pathologic considerations and standardization in mesothelioma clinical trials.
M. Tsao (2019)
Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine
L. Ye (2019)
Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel
A. Marchevsky (2019)
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Y. Metaxas (2020)
Antibody–Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges
Sandrine Payan (2020)